All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Privately held Kalidex Pharmaceuticals Inc. is set to debut on the biotech stage with an oral presentation and two dozen posters on its broad-spectrum, next-generation fluoroquinolone, KPI-10, at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), which begins Sunday in San Francisco.